Myocardial fatty acid (FA) oxidation is regulated acutely by the FA supply and chronically at the transcriptional level due to FA activation of peroxisome proliferator-activated receptor-α (PPARα). In this study we have examined the cardiac response to in vivo administration of tetradecylthioacetic acid (TTA), a pan PPAR agonist. TTA treatment (0.5%, added to the diet, for 8 days) decreased body weight and reduced plasma concentrations of lipids (FA and triacylglycerols) and glucose. Hearts from TTA-treated mice showed an increased mRNA expression of PPARα target genes. In accordance with this observation, myocardial FA oxidation was increased 2.5-fold with a concomitant reduction in glucose oxidation. This increase in FA oxidation was abolished in PPARα-null mice. Thus, it appears that the metabolic effects of TTA on the heart must be due to a stimulatory effect on cardiac PPARα.
INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors regulating transcription of genes encoding proteins that affect lipid metabolism in several tissues, including the heart (21) . Of the PPAR isoforms (α, β/δ, and γ), PPARα is highly expressed in the heart and is thought to play an important role in the transcriptional regulation of cardiac metabolism under both physiological and pathophysiological conditions (6; 13) . Fatty acids (FA) are endogenous activators of PPARs and, accordingly, FA activation of PPARα in isolated cardiomyocytes up-regulates expression of key proteins that regulate nearly every step in the cellular FA utilization pathway, including sarcolemmal FA transport (cellular uptake), FA esterification to triacylglycerols (TG), mitochondrial transport and β-oxidation (16; 33) . Genetically-engineered mouse models with altered PPARα activity have provided further insight regarding the role of these nuclear receptors. PPARα-null mice exhibited diminished rates of cardiac FA oxidation (10; 32) and reduced expression of several genes involved in FA oxidation (36) , whereas cardiac-specific PPARα over-expressing (MHC-PPARα) mice showed increased FA oxidation and up-regulation of genes involved in FA uptake (14; 32) . The contrasting metabolic phenotypes of these two genetically-engineered mouse models support the notion that PPARα plays an important role in regulating cardiac energy metabolism.
Although studies employing isolated cardiomyocytes have shown that PPARα agonists lead to up-regulation of key enzymes in the FA metabolizing pathway (16; 33) , experiments using in vivo administration of PPARα ligands are less clear; some showing up-regulation (22; 30; 37) , while others report minor changes in PPARα target genes in the heart, when compared to the much more pronounced increase in the liver (4; 11; 30) . The effect of in vivo PPARα agonist administration on cardiac substrate metabolism is not well studied. In our own laboratory, we found that in vivo treatment with the PPARα ligand K-111 (previously called BM 17.0744), did not alter FA oxidation in normal mice (2) . In hyperlipidemic animals this treatment even reduced cardiac FA utilization (1; 2), probably a secondary response to reduced plasma FA supply to the heart. Tetradecylthioacetic acid (TTA) is a non-β-oxidizing FA analogue. Although TTA is a pan PPAR agonist (8; 25) , it regulates lipid metabolism mainly through activation of PPARα (25) .
TTA has been shown to increase peroxisomal proliferation and FA oxidation in the liver (8) , lower the concentration of plasma lipids, improve insulin sensitivity and prevent feeding-induced obesity (25) . In this study, oral administration of TTA to mice markedly increased cardiac expression of PPARα target genes and increased FA oxidation, in spite of decreased circulating lipids. In accordance with other studies in which myocardial FA oxidation is increased, these TTA-induced metabolic changes were associated with reduced cardiac efficiency and decreased tolerance to ischemia.
RESEARCH DESIGN AND METHODS

Animals.
Twelve weeks old male and female Balb/c ABomTac mice were purchased from M & B Taconic (Ry, Denmark). In addition, male SVEV129 wild-type (WT) and PPARα-null mice were received as a gift from Dr. Frank J. Gonzalez (National Cancer Institute, Bethesda, MD). The latter groups were bred and housed in the animal facilities at the University of Oxford, UK. All mice were housed in rooms maintained at 21 °C and 55% humidity with a 12-h light/dark cycle with free access to food and water and treated according to the guidelines on accommodation and care of animals formulated by the European Convention for the Protection of Vertebrate Animals for Experimental and Other Scientific Purposes. The experimental groups received food mixed with 0.5% (w/w) TTA for a period of 8 days. Agematched untreated mice served as controls.
Plasma parameters. Plasma glucose, non-esterified FA and TG were determined in blood samples taken from the chest cavity of the animals (non-fasted) at the day of sacrifice, using commercial kits from Boehringer Mannheim (Mannheim, Germany), Wako Chemicals (Neuss, Germany), and ABX Diagnostics (Montpellier, France), respectively.
Real-time quantitative RT-PCR.
Fresh samples from unperfused liver and heart were immersed in RNAlater (Qiagen, Hilden, Germany) and stored at 4 °C until RNA extraction. Heart perfusion. Mice were given an intraperitoneal injection of heparin (100 U) and anesthetized with sodium pentobarbital (10 mg, i.p.). The heart was quickly excised and the aorta cannulated for perfusion in working mode; the left atrium was connected to a preload reservoir (12.5 mm Hg), while the left ventricle was ejecting against an afterload column with a height corresponding to a pressure of 55 mmHg. A modified KHB buffer supplemented with 0.7 mM palmitate (bound to 3% BSA) and 5 mM glucose was used as perfusion medium.
For measurements of cardiac metabolism and susceptibility to ischemia-reperfusion, the hearts were allowed to beat spontaneously, and peak systolic pressure (PSP) was recorded in the aortic line with a Codman Micro Sensor. Coronary flow (CF) was measured by timed collections of the effluent dripping from the heart, while aortic flow (AF) was determined by a drop counter at the outlet of the afterload line. After 30 min perfusion baseline (pre-ischemic) functional parameters were recorded, and thereafter hearts were subjected to 40 min low-flow ischemia (1.68 µl/g dry wt/min) followed by 35 Statistical analysis. Data are expressed as mean ± SEM; mRNA data are normalized to untreated controls. Differences between groups with respect to cardiac mRNA and protein expression, myocardial substrate oxidation and cardiac efficiency were analysed using an unpaired t-test. Differences in substrate oxidation between hearts from TTA-treated and nontreated WT and PPAR-null mice were analysed by two-way ANOVA, followed by HolmSidak´s test. Finally, differences in post-ischemic functional recovery were analysed using repeated measures ANOVA followed by an unpaired t-test. The overall significance level was 0.05.
RESULTS
Biometric data. Eight days treatment with TTA reduced body weight by 8%, as shown in Table 1 ; by comparison, untreated control mice exhibited a 4% increase in body weight. TTAtreatment also resulted in a significant reduction in plasma lipid and glucose levels. Heart weight and liver weight in TTA-treated mice were the same as in controls (Table 1) .
Transcriptional changes in liver and heart and cardiac UCP3 protein expression. In agreement with previous studies (8), TTA-treatment resulted in up-regulation of PPARα target genes in the liver, including lcpt1 (1.9±0.4 fold, p=0.013), pdk4 (4.2±1.2 fold, p=0.006) and ucp2 (2.2±0.4 fold, p=0.008). Analysis of myocardial mRNA levels also showed a significant up-regulation of PPARα-target genes in hearts from TTA-treated mice, including mcpt1, pdk4, ucp3, mte1, cte1, and mcd ( Fig. 1 ). Despite the fact that mRNA expression of ucp3 was markedly increased, UCP3 protein content was unchanged (Fig. 2) .
Myocardial metabolism. Isolated perfused hearts from TTA-treated mice showed a 2.5-fold increase in FA oxidation (Fig. 3A) , with a concomitant decrease (-47%) in glucose oxidation (Fig. 3B) . In order to evaluate whether the TTA-induced changes in cardiac metabolism were (Fig. 3C) . Hearts from TTA-treated WT mice showed markedly increased values of FA oxidation combined with reduced glucose oxidation, whereas TTA had no effect on cardiac metabolism in hearts from PPARα-null mice ( Fig. 3C and D) .
Ventricular function and tolerance to ischemia. Assessment of mechanical function by pressure-volume analysis (Table 2) revealed that TTA-treatment did not alter cardiac function, except for an increased dP/dt max (+18.7%, p<0.02). As increased FA oxidation has been associated with reduced myocardial tolerance to ischemia-reperfusion, hearts were exposed to 40 min low-flow ischemia followed by 35 min reperfusion. Again, we found no differences with respect to pre-ischemic cardiac function (Fig. 4) . TTA-treatment, however, resulted in reduced functional recovery, as indicated by a significant decrease in post-ischemic recovery of aortic flow, cardiac output and rate-pressure product.
Cardiac efficiency. The decreased tolerance to ischemia-reperfusion in hearts with elevated FA oxidation has been associated with and may be caused by decreased cardiac efficiency. In accordance with this we found that TTA-treatment significantly reduced cardiac efficiency (Fig. 5) . This inefficiency was revealed by a 97% increase in unloaded MVO 2 (elevation of the y-intercept of the regression line of the PVA:MVO 2 relationship), while contractile efficiency (the inverse slope of the regression line) was not altered. Myocardial FA oxidation rate is largely determined by lipid supply to the heart. Thus, an acute increase of the plasma lipid level in intact animals (23), or the perfusate FA level in isolated heart perfusions (19), will accelerate myocardial FA oxidation (Randle cycle). It is also known that elevated plasma lipids will increase the reliance on FA as energy substrate in the heart, due to transcriptional changes of metabolic enzymes (PPARα target genes) (6; 13).
Therefore, increased myocardial FA oxidation in type 2 diabetes/obesity is due to increased FA supply, as well as a FA-induced activation of cardiac PPARα. The regulatory role of PPARα in the heart is also demonstrated by increased FA oxidation in MHC-PPARα mice and decreased FA oxidation in PPARα-null mice (10; 14; 32; 36) . In accordance with this, studies on isolated cardiomyocytes have shown that PPARα agonists lead to up-regulation of PPAR target genes, coincided with increased FA oxidation rates (16; 33) . In contrast, studies using in vivo administration of PPARα ligands in normal animals are less clear; increased or unchanged expression of cardiac PPARα regulated genes has been reported (14; 22; 30; 37) , and the changes in the heart is reported to be minor when compared to the more pronounced increase in the liver (4; 11; 30) . The PPAR ligand TTA, produce a large increment in cardiac expression of PPARα target genes and a 2.5-fold increase in myocardial FA oxidation. This finding is in accordance with a previous report showing increased oxidation of palmiotyl CoA in cardiac tissue from rats treated with TTA (17) . The fact that treatment with TTA increased myocardial FA oxidation, despite its hypolipidemic effect, indicates that the effect on cardiac metabolism must be due to changes in gene expression rather than altered FA supply. As the TTA-induced increase in myocardial FA oxidation was abolished in hearts from PPARα-null mice, the cardiometabolic effect of TTA is due to activation of PPARα. Interestingly, hearts from TTA-treated mice showed a metabolic switch towards glucose oxidation by DCA, indicating that these hearts still exhibit metabolic flexibility.
The TTA-induced increase in myocardial FA oxidation is in fact in contrast to studies from our own laboratory; administration of the PPARα ligand K-111 (previously called BM 17.0744) did not alter FA oxidation in normal mice (2), whereas both K-111 (1) and fenofibrate (4) reduced myocardial FA oxidation in hyperlipidemic mice, an effect which was most likely linked to the lipid-lowering effect of these PPARα ligands. Our working hypothesis prior to the present study was therefore that PPARα ligands primarily affect the hearts indirectly through changes in the lipid supply, including endogenous PPAR ligands. As far as we know, this study is the first to report a synthetic PPAR ligand that following in vivo administration to a normal animal, promotes a switch in myocardial substrate preference towards FA. Thus, in conditions with sub-optimal energy production (34), such as hypertrophy and/or heart failure, where carbohydrates is the main energy source, TTA could potentially be used to create an optimal balance between FA and carbohydrate oxidation in the heart.
The discrepancy between the metabolic effect on the heart of TTA on the one side and K-111
and fenofibrate on the other may be related to differences in tissue uptake and/or affinity to cardiac PPARα. TTA is possibly incorporated into chylomicrons during intestinal absorption, taken up in the lymph and subsequently transported to the heart via the blood, allowing efficient uptake of the compound following lipoprotein lipase-catalysed degradation of the chylomicrons. In support of this view Asiedu et al. (5) reported higher concentrations of TTA in heart than in liver of TTA-treated rats.
Both in vivo and ex vivo studies have shown that increased myocardial FA oxidation and/or FA supply to the heart is associated with increased myocardial oxygen consumption (MVO 2 ) and decreased cardiac efficiency (19; 23; 26) , similarly to what has also been reported in diabetic hearts (20) . In accordance with this, TTA-treatment reduced cardiac efficiency, due to a significant increase in unloaded MVO 2 . Since increased MVO 2 may have deleterious consequences, particularly under conditions of limited oxygen supply, narrowing the window of reversible damage, increased MVO 2 is most likely the cause of the decreased post-ischemic function in hearts from TTA-treated mice.
Elevated unloaded MVO 2 (work independent MVO 2 ) reflects increased oxygen cost for nonmechanical purposes such as basal metabolism and excitation-contraction (E-C) coupling. The mechanism explaining this elevation in MVO 2 is not fully understood, but it may involve (i) increased oxygen demand related to the change in fuel consumption from glucose to FA (reduced P:O ratio) (29), (ii) induction of futile cycles, including FA-triacylglycerol cycling (28) and/or increased H + transport due to uncoupling of glucose oxidation from glycolysis (24) , and/or (iii) mitochondrial uncoupling (27) . Himms-Hagen and Harper (18) Lack of functional studies makes it difficult, however, to assign a role of these proteins (UCP3 and MTE-1) in the TTA-induced increase in MVO 2 . Finally, since oxygen consumption in the unloaded heart also includes oxygen cost for E-C coupling, we can not exclude the possibility that the TTA-induced increase in MVO 2 was related to altered cardiac Ca 2+ handling. Indeed, this assumption was supported by the TTA-induced increase in dP/dt max .
In conclusion, the present study has shown that in vivo treatment with TTA, a pan PPAR agonist, leads to a marked increase in myocardial FA oxidation and a decrease in glucose oxidation, a response which was mediated via myocardial PPARα activation. The TTAinduced increase in FA oxidation occurred in the face of decreased circulating lipid levels, demonstrating that PPARα activation can override the impact of the plasma substrate supply on cardiac metabolism. To our knowledge, this study is the first report showing that in vivo administration of a synthetic PPARα ligand increases myocardial FA oxidation. Thus, TTA could potentially be used to maintain an optimal balance between FA and carbohydrate oxidation in the heart, for instance in hypertrophy and/or heart failure where energy requirements are covered mainly by utilization of carbohydrates. 
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